Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Mississippi for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Mississippi only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Mississippi (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Nicole Cleveland (NPI 1639380207)

Field	Value
Entity Type	Individual
Organization	Nicole Cleveland
Address	2969 Curran Dr N
City	Jackson
State	MS
ZIP	39216
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 25, 2007

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider is a medical oncology physician in Jackson, MS with a long Medicare presence; NPI enumeration dates to 2007-05-25 (~19 years ago), indicating nearly two decades of billing history and likely established relationships with local oncology patients and referral sources. The longevity supports an experienced oncology practice rather than a newly established clinic.

Medicare is effectively this provider’s sole payer in the dataset: total Medicare revenue is $2.8M while there is no Medicaid billing on file. The absence of any Medicaid claims indicates a single-payer concentration in the available data and suggests the provider’s commercial/Medicaid participation is either nil or not captured here.

Revenue concentration is substantial: the precomputed top-3 Medicare codes account for 53.8% of total Medicare revenue, indicating over half of this provider’s Medicare dollars come from a small set of high-cost oncology drugs or services. The three highest-revenue codes listed individually include J9271 ($576.2K, 21.4%), J9144 ($519.8K, 19.3%), and J9299 ($353.8K, 13.1%), reflecting a business driven by infused/ injected oncologic agents.

The code mix and top revenue drivers indicate this practice primarily delivers outpatient cancer infusion and biologic therapy: high-revenue HCPCS codes J9271 (pembrolizumab), J9144 (daratumumab with hyaluronidase), and J9299 (nivolumab) are all high-cost immuno-oncology agents, while additional frequent codes include supportive and infusion-related items (e.g., J1568 immune globulin, J2506 pegfilgrastim, and chemotherapy administration codes like 96413). This pattern aligns with an oncology infusion practice that bills both drug and E/M services.

Competitive standing is mixed by code: for J9144 the provider ranks #112 of 615 nationally (81st percentile), and for J1568 the provider ranks #47 of 381 (88th percentile), which indicate above-typical national volume for several supportive and specialty oncology products. Conversely, for J9271 the provider is at the 55th percentile (#806 of 1841) and for J9299 at the 50th percentile (#253 of 505), reflecting typical, unremarkable national volume for some top immunotherapy agents. Overall, the provider is neither universally dominant nor unusually small across oncology drugs—certain products are specialty outliers while others are average.

There are several statistical outliers in the procedural mix that merit attention: the provider ranks #6 of 586 (99th percentile) on J2506 (pegfilgrastim, excludes biosimilar) and is described as an “extreme outlier, far above typical national volume” for that code. The provider similarly ranks in the 99th percentile for office-level codes 99214 (#4443 of 479517) and 99205 (#908 of 66257), also labeled extreme outliers, indicating unusually high billed volumes for both established and new patient E/M visits relative to national peers. These outlier positions suggest concentrated use or preferential billing for specific supportive therapies and high-complexity E/M visits.

Operational breadth includes both drug administration and associated E/M and lab services: beyond high-revenue injectable oncology drugs, the provider bills routine lab panels (80053, 85025, 82728) and infusion administration codes (96413, 96401, 96417, 96365). This spread implies the practice captures both drug-reimbursement and ancillary revenue streams typical of infusion-centric oncology practices, supporting care continuity within the same billing entity.

From a payer strategy perspective, the absence of Medicaid billing means payers and network managers should treat this entity as a Medicare-centric revenue source in the available data; contracting, utilization review, and network adequacy assessments should account for concentrated Medicare drug spend and select extreme-volume codes (pegfilgrastim and high-level E/M) that disproportionately drive payment. If Medicaid access or coverage expansion is a policy goal, outreach or credentialing inquiries may be needed since no Medicaid activity is recorded.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

77 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,400	$40	$576.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	13,680	$40	$519.8K
J9299	Injection, nivolumab, 1 mg	14,740	$20	$353.8K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	7,420	$30	$244.9K
J0897	Injection, denosumab, 1 mg	12,000	$20	$216K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,550	$90	$131.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,400	$90	$120.6K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	4,490	$30	$112.2K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	10,500	$10	$105K
J1439	Injection, ferric carboxymaltose, 1 mg	75,000	$1	$75K

Showing 1–10 of 77

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 77 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Mississippi Distribution

Nicole Cleveland — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Mississippi

Full comparison — all codes billed, vs. state median

77 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	10	16,700	$40	$1M
J9144	2	10	13,050	$40	$631.7K
J9299	6	10	21,120	$20	$569.7K
J1568	3	10	7,420	$30	$393.8K
J1449	4	10	4,160	$30	$149.3K
J9264	3	10	14,550	$10	$145.7K
J0897	16	110	3,030	$20	$95.7K
J2506	3	10	910	$80	$91.5K
J1439	3	20	42,000	$1	$41.6K
J0185	4	10	18,330	$1	$26.4K

Showing 1–10 of 77

Related Providers

Other providers that share a Tax Identification Number (TIN) with Nicole Cleveland, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Guangzhi Qu	MS	Hematology & Oncology Physician	$9.1M	$0
Tammy Young	MS	Medical Oncology Physician	$5.1M	$0
Justin Baker	MS	Hematology & Oncology Physician	$4.1M	$0
Thomas Williamson	NC	Hematology & Oncology Physician	$2.4M	$0
Manubhai Patel	MS	Medical Oncology Physician	$1.9M	$0
Elizabeth Herrington	MS	Medical Oncology Physician	$1.9M	$0
Natale Sheehan	MS	Medical Oncology Physician	$1.4M	$0
Bobby Graham	MS	Hospice and Palliative Medicine (Internal Medicine) Physician	$143.8K	$0
Donald Tisdale	MS	Family Nurse Practitioner	$113.4K	$0
Meaghan Johnson	MS	Family Nurse Practitioner	$98.5K	$0

Nearby Providers

Other providers in the same ZIP code as Nicole Cleveland, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
State Of Mississippi - University Of Mississippi Medical Center	MS	General Acute Care Hospital	$0	$507.2M
Central Ms. Planning & Dev. District, Inc.	MS	Case Management Agency	$0	$47.2M
St Dominic-jackson Memorial Hospital	MS	General Acute Care Hospital	$0	$37.1M
Afnb Home Care LLC	MS	In Home Supportive Care Agency	$0	$25.6M
Ms Children's Home Society	MS	Community/Behavioral Health Agency	$0	$19.4M
Mississippi State Department Of Health	MS	Community/Behavioral Health Agency	$0	$14.9M
Ms State Department Of Health	MS	Community/Behavioral Health Agency	$0	$14.5M
Mississippi Asthma & Allergy Clinic PA	MS	Allergy & Immunology Physician	$0	$8.2M
Mississippi Methodist Hospital & Rehabilitation Center, Inc.	MS	General Acute Care Hospital	$0	$5.7M
Jerrick Rose	MS	Pediatric Dentistry	$0	$4.6M

Nicole Cleveland — Billing Profile & Reimbursement Data

Sign up for Nicole Cleveland — Billing Profile & Reimbursement Data policy alerts

Nicole Cleveland — Billing Profile & Reimbursement Data

Sign up for Nicole Cleveland — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References